Fast-acting insulin aspart delivered through a hybrid closed-loop insulin delivery system provided similar glycemic outcomes as standard insulin aspart for young children with type 1 diabetes ...

The rapid-acting insulin should be administered subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm.

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

Depending on the pharmacy, Semglee injector pens cost about $150 to $190 without insurance for a typical month's supply, compared to $340 to $520 for the same supply of Lantus. Insulin prices have ...

Sanofi-Aventis' Merilog is the first FDA-approved rapid-acting insulin biosimilar. On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and ...

The smart pen cap for rapid-acting insulin allows the user to scan the FreeStyle Libre 2 sensor, displaying the user’s current glucose value, trend arrow and any recommended correction dose.

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. It will be available as a ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be available via prefilled pens and vials ...

According to the FDA, more than 38 million people in the United States have been diagnosed with diabetes, and approximately 8.4 million Americans rely on insulin therapy, either rapid-acting or ...

Merilog has been approved as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. The approval is for both a 3 ...

Discover the latest breakthrough in diabetes treatment with Sanofi-Aventis' Merilog, the first FDA-approved rapid-acting insulin biosimilar.